Neurogene is said to offer new shares at 4.6% discount to close
Neurogene Inc. (NASDAQ: NGNE) has announced the issuance of new shares at a 4.6% discount to the closing price of its common stock. This development follows the company’s recent private investment in public equity (PIPE) financing, which raised approximately $200 million in gross proceeds. The new shares were issued as part of a broader capital-raising initiative to support ongoing clinical trials and the development of its gene therapy pipeline.
The issuance of these shares is tied to the company’s 2024 Registration Rights Agreement, which obligates Neurogene to register the resale of shares issued in the PIPE and those issuable upon the exercise of pre-funded warrants. The pre-funded warrants were sold at a price of $49.999 per share, with an exercise price of $0.001 per share, effectively offering a nominal discount to the closing price of $50.00 per share. This structure allows the company to raise capital while providing investors with flexibility in the timing of their equity conversion.
Neurogene expects the net proceeds from the PIPE financing, combined with its existing cash reserves, to fund operations through the second half of 2027. The capital will be allocated toward the completion of a registrational study for NGN-401, a gene therapy candidate for Rett syndrome, as well as the scale-up of manufacturing capabilities and further development of its EXACT™ gene therapy platform.
The company also announced the appointment of Christy Shafer as its new Chief Commercial Officer, accompanied by inducement stock option grants in May 2026. These grants are part of the company’s broader strategy to strengthen its leadership team and advance its commercialization goals.
Neurogene’s shares are currently listed on the Nasdaq Global Market under the ticker symbol NGNE. As of March 21, 2025, the last reported sale price for the stock was $14.21 per share. The company remains subject to the regulatory and market risks typical of clinical-stage biotechnology firms, including uncertainties related to clinical trial outcomes and regulatory approvals.
Investors should consider the implications of the recent share issuance, including potential dilution and the impact on market price volatility. The company has emphasized that it will not receive proceeds from the resale of shares by selling stockholders, though it will receive nominal cash from the exercise of pre-funded warrants.
